Medorbis Trade LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Medorbis Trade LLP Pharmaceutical Export Portfolio Dataset — 4 Products, $870.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medorbis Trade LLP — Pharmaceutical Exporter Profile (2026) | 4 Products, $870.8K Trade | TransData Nexus

Product Portfolio — Top 4 by Export Value

Medorbis Trade LLP exports 4 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Fluorouracil	Oncology	$262.8K	17	2.1%	8
2	Cisplatin	Oncology	$208.8K	11	1.6%	11
3	Etoposide	Oncology	$200.0K	4	1.8%	6
4	Cytarabine	Advanced Oncology	$199.1K	10	1.9%	8

Medorbis Trade LLP exports 4 pharmaceutical products across 2 therapeutic categories with a total export value of $870.8K. The top category is Oncology (77.1% of portfolio), followed by Advanced Oncology (22.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Medorbis Trade LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Medorbis Trade LLP is a pharmaceutical export company based in Mumbai, Maharashtra, India. Established on May 26, 2018, the company operates under the Corporate Identification Number (CIN) AAM-7117. The registered office is located at 304 Town Centre, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra, 400059.

The ownership structure of Medorbis Trade LLP is predominantly held by its promoters, who own 92.83% of the company. The remaining shares are distributed among public shareholders (4.10%) and other entities (3.07%). The company has a paid-up capital of ₹1,50,000.

2Manufacturing Facilities

Specific details regarding Medorbis Trade LLP's manufacturing facilities, including their locations, capacities, and specializations, are not publicly disclosed. The company's export activities primarily involve finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections. However, information about the manufacturing processes and facilities remains limited.

3Key Leadership

The leadership team of Medorbis Trade LLP comprises the following designated partners:

Mohan Babulal Jain
Manish Babulal Jain
Aarya Mohan Jain

These individuals have been associated with the company since its inception on May 26, 2018. Aarya Mohan Jain joined as a designated partner on June 2, 2025.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Medorbis Trade LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Medorbis Trade LLP's export activities are primarily focused on the oncology segment, with a portfolio comprising finished pharmaceutical formulations such as Fluorouracil, Cisplatin, Etoposide, and Cytarabine. The company's total export value stands at $871,000 USD, with 42 shipments across four products in two therapeutic categories. The top five products include Fluorouracil ($263,000, 2.1% market share), Cisplatin ($209,000, 1.6% market share), Etoposide ($200,000, 1.8% market share), and Cytarabine ($199,000, 1.9% market share). The oncology category accounts for 77.1% of the portfolio, while advanced oncology contributes 22.9%. The company's portfolio is highly concentrated, with the top five products comprising 100% of the export value.

2Emerging Markets

Medorbis Trade LLP has established a presence in emerging markets, particularly in Latin America. The company's export data indicates significant shipments to countries such as Colombia and Nicaragua, with 69.92% and 27.94% of export shipments respectively. While specific details regarding WHO prequalification are not available, the company's engagement in these markets suggests a strategic approach to expanding its footprint in regions with growing pharmaceutical demand.

3Geographic Strategy

Medorbis Trade LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Medorbis Trade LLP's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export activities primarily focus on markets outside the United States, and there is no publicly disclosed evidence of FDA approvals or registrations.

2WHO & EU GMP

Details regarding Medorbis Trade LLP's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed. The company's export activities are concentrated in markets where such certifications may not be mandatory.

3CDSCO & Indian Regulatory

Medorbis Trade LLP operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available. The company's export activities suggest compliance with Indian regulatory requirements, but detailed information is not disclosed.

Medorbis Trade LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Medorbis Trade LLP operates in the competitive pharmaceutical export market, focusing on oncology products. While specific competitors are not identified, the company's export data indicates significant shipments to Latin American countries, suggesting competition with other pharmaceutical exporters in these regions. The company's specialized product portfolio may provide a competitive edge in niche markets.

2Key Differentiators

Medorbis Trade LLP's key differentiators include its specialized focus on oncology products and a concentrated export portfolio. This specialization allows the company to leverage expertise in a specific therapeutic area, potentially offering high-quality products tailored to market needs. However, the lack of diversification may expose the company to risks associated with market fluctuations in its primary export destinations.

3Strategic Position

Medorbis Trade LLP's current strategic direction appears to be focused on exporting finished pharmaceutical formulations in the oncology segment to select international markets. The company's future outlook may involve expanding its product portfolio, diversifying export destinations, and seeking certifications such as WHO prequalification and EU GMP to enhance market access and credibility.

Buyer Due Diligence Brief — Evaluating Medorbis Trade LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Medorbis Trade LLP's export data indicates a consistent volume of shipments, primarily to Latin American countries. The company's specialization in oncology products suggests a reliable supply chain capable of meeting the demands of its export markets. However, the lack of publicly available information regarding manufacturing facilities and regulatory certifications makes it challenging to fully assess the company's reliability and compliance standards.

2Certifications to Verify

Importers should verify the following certifications when considering Medorbis Trade LLP as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

WHO-GMP Certification: Verify compliance with World Health Organization Good Manufacturing Practices.

EU GMP Certification: Ensure adherence to European Union Good Manufacturing Practices.

Frequently Asked Questions — Medorbis Trade LLP

How many pharmaceutical products does Medorbis Trade LLP export from India?

Medorbis Trade LLP exports 4 pharmaceutical products across 2 therapeutic categories. The top exports are Fluorouracil ($262.8K), Cisplatin ($208.8K), Etoposide ($200.0K), Cytarabine ($199.1K). Total export value is $870.8K.

What is Medorbis Trade LLP's total pharmaceutical export value?

Medorbis Trade LLP's total pharmaceutical export value is $870.8K, based on 42 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Medorbis Trade LLP cover?

Medorbis Trade LLP exports across 2 therapeutic categories. The largest are Oncology (77.1%, 3 products), Advanced Oncology (22.9%, 1 products).

Get Full Medorbis Trade LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Medorbis Trade LLP

Medorbis Trade LLP — Export Portfolio & Destination Treemap

Who is Medorbis Trade LLP? — Company Overview & Market Position

What Does Medorbis Trade LLP Export? — Product Portfolio Analysis

Top Products by Export Value

Medorbis Trade LLP Therapeutic Categories — 2 Specializations